A Clinical Study To Assess the Efficacy & Safety of Stonvil Capsules (Ayurvedic Formulation)for the treatment of Recurrent Urinary Tract Infections associated with Renal Calculi.

An Open Labelled , Interventional, Single Centric Clinical Study To Assess the Therapeutic Efficacy & Safety of Stonvil Capsules for the treatment of Recurrent Urinary Tract Infections associated with Renal Calculi.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/02/007784

Enrollment

Registered

2017-02-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Recurrent Urinary Tract Infections associated with Renal Calculi

Interventions

Intervention1: Stonvil Capsules: Each Stonvil Capsule Contains : Punarnava-20mg Saag Beej-20mg Gudmar-30mg Gokshuradi Guggul-50 mg Apamargkshar-30mg Pashanbhed-30mg Shilajit-40mg Dagdibher Bhasma-60mg

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male and Female subjects of age 18 years and above. 2.Subjects reported with Renal Calculi, while investigatorâ??s assessment. 3.History of recurrent Urinary Tract Infections (3 or more confirmed UTIâ??s in the past 6 â?? 12 Months). 4.Subjects with Urinary Tract Infections, as confirmed by Urinalysis. 5.Subjects with symptoms of Urinary Tract Infections like Cloudy or Bloody Urine, which may have foul or strong odor, Painful or burning micturition, Pressure or Cramping in lower abdomen or back, Strong need to urinate often, even right after the bladder has been emptied etc. 6.Subjects who are not taking any other medication for Urinary Tract Infection. 7.Be informed of the nature of the study and will give written informed consent. 8.Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion criteria: 1.Complicated cases of Renal Calculi requiring surgery. 2.Subjects taking herbal supplements for Renal Calculi or Urinary Tract Infections within previous 30 days. 3.Evidence of significant, uncontrolled concomitant disease which in the investigatorâ??s opinion would preclude subject participation. 4.Females of childbearing age without adequate contraception. 5.Use of disallowed concomitant medications. 6.Any disease or condition which might compromise the hematopoietic, renal, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system. 7.Use of any recreational drugs or a history of drug addiction and chronic alcoholics. 8.Patient not willing to sign informed consent.

Design outcomes

Primary

Measure	Time frame
Primary Outcome: Reduction in Symptoms of Recurrent Urinary Tract Infection as compared to Baseline Visit.Timepoint: 20 Days	—

Secondary

Measure	Time frame
Secondary Outcomes: Assessment of Adverse Events associated with the treatment. Timepoint: 20 Days	—

Countries

India

Contacts

Public ContactMr Kamal Kammili

Sanjeevani Bio Services Pvt. Ltd.

srinivas.lanka@sanjeevanibio.com04065794774

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026